Management of dengue
Reading File
Finding Sources
Searching PubMed
dengue fever management treatment
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
WHO dengue management guidelines 2024 fluid therapy severe dengue
Reading File
Reading File
Reading Web Page
dengue management fluid therapy groups treatment
I now have comprehensive information from multiple authoritative sources. Let me compile a thorough, well-structured answer.
Management of Dengue
Overview
Dengue is caused by four antigenically distinct RNA flaviviruses (DENV 1-4), transmitted by Aedes aegypti mosquitoes. There is no specific antiviral therapy. Management is entirely supportive, but timely, appropriate fluid management dramatically reduces mortality from ~5-10% to <1%.
WHO Classification (2009) - Clinical Staging
The first step in management is classifying severity, as this dictates the treatment group:
| Category | Criteria |
|---|---|
| Dengue without warning signs | Fever + 2 of: nausea/vomiting, rash, aches, leukopenia, positive tourniquet test |
| Dengue with warning signs | Above + abdominal pain/tenderness, persistent vomiting, fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy/restlessness, liver enlargement >2 cm, progressive hematocrit rise |
| Severe dengue | Severe plasma leakage with shock/respiratory distress, clinically significant bleeding, severe organ involvement (ALT/AST >1000 IU/L, impaired consciousness, cardiac failure) |
Phases of Illness and Clinical Correlates
- Febrile phase (days 1-3): Abrupt high fever, myalgia, arthralgia, retro-orbital pain, facial erythema, leukopenia. Treat fever, encourage oral hydration.
- Critical phase (days 3-7, around defervescence): Plasma leakage due to increased vascular permeability, rising hematocrit (hemoconcentration), rapid platelet fall. Risk of shock, effusions, bleeding. This phase typically lasts 24-48 hours and is the danger window.
- Convalescent phase: Reabsorption of extravascular fluid, risk of fluid overload and dilutional drop in hematocrit. Diuresis occurs. Watch for bradycardia and fluid overload.
Treatment Groups and Management Approach (CDC 2024 / WHO)
Group A - Outpatient Management
- Dengue without warning signs AND able to tolerate oral fluids
- Treatment:
- Adequate oral hydration (water, ORS, juice - at least 2 L/day in adults)
- Paracetamol for fever (max 4 g/day in adults) - avoid aspirin and NSAIDs
- Rest
- Monitor for warning signs; return immediately if they develop
- Follow-up within 24 hours near defervescence (days 3-5)
- Check CBC every 24-48 hours
Group B - Inpatient Management
B1 - Coexisting conditions or social risk (no warning signs):
- Obtain IV access
- Encourage oral fluids; start IV crystalloids at 2-4 mL/kg/hr if not tolerating oral intake
- Stop IV fluids once oral fluids are tolerated
- Monitor vital signs, urine output, CBC
B2 - Dengue with warning signs:
- Obtain IV access and CBC
- Administer IV crystalloid (isotonic - normal saline or Lactated Ringer's) at 10 mL/kg over 1 hour
- Reassess every 1-4 hours
- If improving (stable hematocrit, urine output >1 mL/kg/hr): reduce to 5-7 mL/kg/hr for 2-4 hrs, then 3-5 mL/kg/hr, then 2-4 mL/kg/hr
- If not improving: repeat 10 mL/kg bolus (up to 2 times); if still failing - escalate to Group C management
- Monitor vital signs, hematocrit, platelets, and urine output continuously
Group C - Inpatient Management for Severe Dengue / Shock
- Dengue with shock or respiratory distress, clinically significant bleeding, or severe organ failure
- Compensated shock: IV crystalloid at 10-20 mL/kg over 15-30 minutes; can repeat up to 3 doses (total 60 mL/kg)
- Hypotensive shock / refractory shock: IV colloids (e.g., dextran 40, hydroxyethyl starch) preferred after initial crystalloid trials
- Target: urine output >1 mL/kg/hr, resolution of shock signs, stabilization of hematocrit
- If hematocrit falls significantly (dilutional, suggesting occult bleeding): consider packed RBCs
- ICU-level monitoring required
Fluid Management Principles
- Maintenance of intravascular volume is the single most critical intervention
- Crystalloids first (normal saline or Ringer's lactate); use colloids for refractory shock
- Avoid fluid overload - reabsorption of plasma during convalescence can cause dilutional hyponatremia and pulmonary oedema
- Hematocrit is a key surrogate for plasma leakage - a rising Hct signals ongoing extravasation; a falling Hct may indicate haemodilution (recovery) or haemorrhage
- Fluid restriction during convalescent phase; watch for signs of overload (falling Hct with persistent tachycardia, respiratory distress)
Medications: DOs and DON'Ts
| Use | Avoid |
|---|---|
| Paracetamol (acetaminophen) for fever and pain | Aspirin |
| Oral rehydration solution | NSAIDs (ibuprofen, naproxen, diclofenac) - increase bleeding risk |
| IV crystalloids when indicated | Corticosteroids (no proven benefit, not routinely recommended) |
| Platelet or blood transfusion when clinically indicated | Prophylactic platelet transfusion for thrombocytopenia alone |
On platelet transfusion: Transfusion is reserved for clinically significant bleeding with severe thrombocytopenia. Prophylactic platelet transfusions are NOT recommended - thrombocytopenia alone (even counts <10,000) in the absence of bleeding is not an indication.
Monitoring Parameters
During the critical phase, monitor every 1-4 hours:
- Vital signs (BP, HR, temperature, RR)
- Urine output (target >1 mL/kg/hr; oliguria signals shock)
- Hematocrit (serially - hemoconcentration precedes shock)
- Platelet count
- Blood glucose
- Liver function (AST/ALT) for hepatitis
- Signs of fluid overload (bilateral crackles, effusions, worsening oedema)
Specific Complications and Management
| Complication | Management |
|---|---|
| Dengue shock syndrome (DSS) | Aggressive IV fluid resuscitation, colloids if refractory, ICU care |
| Severe bleeding | Packed RBCs, fresh frozen plasma, platelet concentrate as clinically indicated |
| Hepatitis (ALT/AST >1000) | Avoid hepatotoxic drugs, supportive care; may require ICU |
| Encephalitis/neurologic | Supportive; rule out bacterial coinfection |
| Myocarditis | Cardiac monitoring; avoid fluids in cardiogenic shock |
| Haemophagocytic lymphohistiocytosis (HLH) | Rare but serious; consider if persistent fever with cytopaenias and elevated ferritin |
| Acute kidney injury | Careful fluid balance, avoid nephrotoxins; dialysis if severe |
Vaccination
- Dengvaxia (CYD-TDV): Recombinant live-attenuated tetravalent dengue vaccine; 3 doses at 0, 6, and 12 months
- FDA-approved in the US for ages 9-16 years who are seropositive (prior dengue infection confirmed)
- Seronegative individuals must NOT receive Dengvaxia - vaccination in seronegative individuals paradoxically increases risk of severe dengue on subsequent infection (antibody-dependent enhancement)
- Pre-vaccination serology is required
Isolation and Infection Control
- Standard precautions in hospital (bloodborne transmission potential)
- Isolate febrile patients from mosquito exposure to prevent secondary transmission - a viraemic patient bitten by an Aedes mosquito can perpetuate the outbreak cycle
Key Takeaways
- No antiviral therapy exists - management is supportive
- Correct classification into Groups A/B/C drives all treatment decisions
- The critical phase (around defervescence, days 3-7) is when plasma leakage and shock occur
- IV fluid management with close monitoring is the cornerstone of severe dengue treatment
- Avoid aspirin, NSAIDs, and prophylactic steroids
- Early recognition of warning signs reduces mortality from ~10% to <1%
Sources:
- Red Book 2021 (Committee on Infectious Diseases), pp. 520-524
- Rosen's Emergency Medicine, p. 2630
- Washington Manual of Medical Therapeutics, p. 570
- Harrison's Principles of Internal Medicine 22E (2025)
- CDC Dengue Case Management Pocket Guide (2024)
- PAHO Clinical Management Algorithms (2024)
Recent evidence note: A 2025 systematic review (PMID 41037858, J Infect Public Health) on dengue pathogenesis, diagnosis, and management is consistent with the above guidelines. Two recent meta-analyses (2024) identified predictors of dengue-associated AKI (PMID 39300514) and HLH (PMID 38721675) as emerging concerns in severe disease.
This is a shared conversation. Sign in to Orris to start your own chat.